REDDIE Consortium Holds Annual General Assembly Meeting

On November 20, members of the REDDIE consortium gathered virtually for the Annual General Assembly meeting. Approximately 25 participants attended the meeting, including different stakeholders such as industry partners, patient advisory committee members, and REDDIE advisory board representatives.

Since we are halfway to the end of the project, the meeting served to review progress across all work packages. REDDIE project manager Martina Radanović from RISE opened the meeting, highlighting the deliverables completed and the ones that await us at the end of next year.

Key discussions centred on tasks, deliverables, and advancements in utilising real-world data (RWD) to complement randomised controlled trials (RCTs). By leveraging data from national registries in (Sweden, Denmark, Germany, and the UK), the consortium aims to replicate RCT outcomes and assess if RWD can improve the efficacy, safety, and value for money of technologies to prevent and treat diabetes. Additionally, the integration of data from devices, wearables, and electronic health records within these registries highlights opportunities to evaluate innovative technologies, particularly in managing chronic conditions like diabetes mellitus. The discoveries will allow us to provide guidelines on RWD assessment for regulatory authorities.

REDDIE's Project Manager, Martina Radanović, emphasised the importance of regular General Assembly meetings in order to keep the consortium members informed on the project alignment and proactively address challenges.

The next REDDIE consortium gathering is scheduled for March 2025, when partners will meet in Padua, Italy, hosted by University of Padua.